pharmaceuticals

There are opportunities for biotech investors to profit at each stage of clinical trials.

With its low payout ratio and booming free cash flow, this pet pharmacy is a dividend investor’s best friend.

Pfizer’s struggles with free cash flow and dividend cuts may have a silver lining if its growth meets expectations.